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ARTICLE INFO  ABSTRACT 
 
 
SARS-CoV-2 belongs to the Coronaviridae family and of the order Nidovirales, which has 
positive non-segmented RNA, of the enveloped type that causes a severe acute respiratory 
syndrome in humans, which has already infected more than 9 million people worldwide, leading 
to 496,075 deaths by June 27, 2020, making the search for alternative treatment for this pathogen 
urgent. Thus, this study aimed to conduct a bibliographic survey of research that presents 
treatment alternatives for the new coronavirus. Thus, a qualitative and descriptive cross-sectional 
study was carried out, and a comparative analysis was carried out with the prospective results 
achieved as presented in a study carried out by Reis and collaborators. Publications from the last 7 
months were considered, that is, from December 2019 to June 2020, the period in which studies 
of SARS-CoV-2 started. In this way, a total of 4,898 studies related to the treatment alternative 
for SARS-CoV-2 were found, in which the drugs remdesivir, atazanavir, favipiravir, EIDD-2801 
and hydroxychloroquine associated with azithromycin stand out, where they presented attractive 
preliminary results and are recommended for clinical studies in humans as an alternative way of 
coping with the new coronavirus. 
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In Wuhan, the capital of Hubei province, China, there have 
been cases of pneumonia of unknown cause, where most of the 
diagnosed people worked or lived near the local Huanan 
wholesale seafood market, which sold live animals for 
consumption. This disease soon spread and the city became the 
center of an outbreak of severe acute respiratory syndrome 




the etiologic agent of this disease was made by the Chinese 
Center for  Disease  Control  and Prevention (CDC) on January 
7, 2020, where the new coronavirus classified as SARS-CoV-2 
(Severe acute respiratory syndrome coronavirus 2) and known 
popularly as COVID-19 (Zhou et al., 2020). However, only in 
February 2020, the virus was officially released by the World 
Health Organization (WHO) as the cause of the new 
respiratory disease (Gorbalenya, 2020). This is the 9th 
identified coronavirus that infects humans, belonging to the 
Coronaviridae family and of the order Nidovirales that have 
positive non-segmented RNA, of the enveloped type (Huang et 
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al., 2020). SARS-CoV-2 infection can range from mild 
symptoms of the upper respiratory tract to severe viral 
pneumonia with respiratory failure and can lead to death (Chen 
et al., 2020; Andersen et al., 2020). The symptoms vary 
according to the immune characteristics of the person infected 
by the virus, and may present fever, irritation in the throat, loss 
of smell and taste, headache, muscle pain, difficulty in 
breathing and radiological opacity of the lung in frosted glass 
in the most severe cases (Corman et al., 2020). On June 27, 
2020, the virus had infected 9,891,727 people worldwide, 
leading to 496,075 deaths (https://coronavirus.jhu.edu/ 
map.html) (Johns Hopkins University [website] (2020). This 
number tends to increase, as there is no treatment for COVID-
19. In this way, WHO recommends social isolation to try to 
reduce the contagion and prevent a collapse in the health 
systems of the country’s most affected by the disease (Chen et 
al., 2020; Gorbalenya, 2020). Currently, South America is the 
new epicenter of COVID-19, with Brazil being the country 
most affected, with 1,274,974 confirmed cases and 55,961 
deaths (Johns Hopkins University [website] (2020). In this 
perspective, the search for an effective treatment has been the 
priority of scientists worldwide, developing studies of drug 
repositioning, clinical presentations, traditional Chinese 
medicine and studies with advanced therapy drugs (Cattani, 
2020; Araújo et al., 2020). Thus, this study aimed to carry out a 
bibliographic survey of research that presents treatment 




The study is qualitative in nature and cross-sectional, with a 
comparative analysis carried out with the prospective results 
achieved, as presented in a study carried out by Reis and 
collaborators (Dos Reis et al., 2016). The prospective study 
followed the method of Martins and collaborators (Martins et 
al., (2020) with some modifications. The search in the 
databases was carried out between the months of May and June 
2020, where publications from the last 7 months were 
considered, that is, from December 2019 to June 2020. This is 
the period when studies of SARS-CoV-2 started. Only studies 
in English (American and British) were considered. The 
databases used in this search were: Centro Latino-Americano e 
do Caribe de Informação em Ciências da Saúde (Bireme), 
Directory of Open Access Journals (DOAJ), American 
Chemical Society (ACS), Portal de Periódicos CAPES 
(CAPES/MEC) and National Center for Biotechnology 
Information (PubMed). Searches for paper were also carried 
out on the preprint Server for Chemistry (ChemRxiv), because 
due to the need to seek studies aimed at alternative treatment 
against COVID-19, it is essential to elucidate preliminary 
results available as a preprint. Thus, studies that point to 
possible treatment alternatives for SARS-CoV-2 were selected 
to elucidate the treatment alternatives found against COVID-19 
and which are more promising (Carvalho et al., 2020). The 
descriptors used were: drugs against SARS-CoV-2, COVID-19 





The findings point to significant numbers of studies related to 
alternative treatment for SARS-CoV-2, using the databases, 
Bireme, DOAJ, ACS , CAPES/MEC, and PubMed, where 
2,897 published studies were obtained and evaluated by peers 
in scientific journals. Searches for paper were also carried out 
on the preprint Server for Chemistry (ChemRxiv), with 2,001 
preprints found. These searches took into account articles 
published between the months of December 2019 to June 2020. 
In graphs 1, 2 and 3, we can elucidate the amount of searches 
found for each descriptor. The descriptor “drugs against SARS-
CoV-2” presented the largest number of published studies, with 
a total of 1,826 articles. We can see in Graph 1 that most of 
these studies are concentrated in the ChemRxiv database, 
containing 659 articles related to research on drug 
repositioning against the new coronavirus, where we highlight 
the drugs arbidol, remdesivir, favipiravir (Dong et al., 2020), 
lopinavir/ritonavir  (Mckee et al., 2020), chloroquine, 
atazanavir, rimantandine, amantadine, zanamivir, oseltamivir 
(Araújo et al., 2020), hydroxychloroquine (Eastman et al., 
2020), EIDD-2801, baricitinib, methylprednisolone, heparin, 
zinc, darunavir, emtricitabine, tenofovir, fingyrpridam, 
baloxaviram, marxaviram losartan, azithromycin, ribavirin, 
triazavirin, tranilast, ebastine (Huang et al., 2020). We 
emphasize that these results were obtained through filtering, 
using tools available in the databases, excluding observational 
studies, divided into descriptive and analytical, taking into 
account only studies of innovative discovery of treatment 
alternatives for SARS-CoV-2. The DOAJ database had the 





Graph 1: Studies found for the descriptor “drugs against SARS-CoV-2”. 
Note: Bireme - Centro Latino-Americano e do Caribe de Informação em Ciências da 
Saúde; DOAJ - Directory of Open Access Journals; ACS - American Chemical Society; 
CAPES/MEC - Portal de Periódicos CAPES; PubMed - National Center for 
Biotechnology Information; ChemRxiv - preprint Server for Chemistry. Source: 




Graph 2: Deposits of articles referring to the descriptor “COVID-19 target 
protein inhibitors”. 
 
Note: Bireme - Centro Latino-Americano e do Caribe de Informação em Ciências da 
Saúde; DOAJ - Directory of Open Access Journals; ACS - American Chemical Society; 
CAPES/MEC - Portal de Periódicos CAPES; PubMed - National Center for 
Biotechnology Information; ChemRxiv - preprint Server for Chemistry. Source: 
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Graph 2 shows the results obtained in the search for scientific 
articles on research involving the inhibition of SARS-CoV-2 
key proteins by means of organic or synthetic compounds. 
1,139 studies were found related to the descriptor “COVID-19 
target protein inhibitors”, which the lowest result is found in 
comparison to the other descriptors. This demonstrates that 
most studies are focused on research with drugs already 
available on the market, as these have already undergone 
regulatory processes and tests of their pharmacological and 
toxic properties and become attractive in studies in the short or 
medium term (Liu et al., 2020). The database with the most 
publications was ChemRxiv with 517 results (Graph 2). 
According to the author Huang and collaborators (Huang et al., 
2020), there are 19 inhibitors under study with biological 
potential to treat the new coronavirus, among them, 4 stand out 
with excellent binding-free energy when they bind to a key 
SARS-CoV-2 protein by molecular docking studies, they are: 
patchouli alcohol; resveratrol; lignan; and curcumin. 
 
For the descriptor “vaccines against the new coronavirus”, 
1,933 results from published articles were achieved, with the 
ChemRxiv database prevailing with the largest number of 
articles, and the DOAJ with the lowest amount, only 23 articles 
published on studies of vaccines that are effective against the 
SARS-CoRV-2 (Graph 3). It can be seen that the ChemRxiv 
database presented a greater number of published studies 
among all the other databases for the 3 descriptors used in this 
study, this was already expected, since preprint studies were 
not evaluated by peers and are not published in scientific 
journals, in this way, research is deposited at ChemRxiv 
simultaneously after submission (Huang et al., 2020). This 
resource is a way for scientists to share preliminary or 
completed results of studies against SARS-CoV-2 so that they 
can disseminate information as soon as possible to the 
scientific community due to the need to find an alternative 
treatment for the new coronavirus. According to Canaday and 
collaborators (Canaday  and Gravenstein, 2020), in their 
research entitled “On setting expectations for a SARS-CoV-2 
Vaccine”, there was a major international effort to develop a 
vaccine against SARS-CoV-2 in less than 6 months, thus 
generating more than 140 vaccines at different stages of 
development, with 9 recruited for clinical trials, with Oxford 




Graph 3: Studies found for the descriptor "vaccines against the new 
coronavirus". 
 
Note: Bireme - Centro Latino-Americano e do Caribe de Informação em Ciências da 
Saúde; DOAJ - Directory of Open Access Journals; ACS - American Chemical Society; 
CAPES/MEC - Portal de Periódicos CAPES; PubMed- National Center for Biotechnology 
Information; ChemRxiv - preprint Server for Chemistry.  
Source: Developed by the authors (2020). 
DISCUSSION 
 
Currently, large pharmacological companies and infectious 
disease research groups are focused on developing an anti-
SARSCoV-2 vaccine, or discovering an alternative treatment 
that can inhibit the virus, thus the search for vaccines, 
monoclonal antibodies and drugs are the studies developed by 
scientists around the world (Nutho et al., 2020). However, 
these studies need time to elucidate their pharmacological, 
toxicological properties, active potential, in addition to 
analyzing the effectiveness of these possible drugs, vaccines 
and SARS-CoV-2 inhibitors (Nutho et al., 2020). We observed 
that most of the studies found by these descriptors, are aimed at 
research on drug redirection (Liu et al., 2020), where it is 
possible to identify attractive anti-SARS-CoV-2 biological 
activity of drugs of a given pathogen and redirect them to the 
treatment of COVID -19. This reuse can be implemented 
through the systematic realization of drugs, target drug action 
(DTI) and therapeutic interaction analysis (DDI) (Canaday, and 
Gravenstein, 2020). In this perspective, we present the drugs 
that are being studied in clinical trials and computational 
prediction studies, they are: arbidol, remdesivir, favipiravir, 
lopinavir / ritonavir, chloroquine, atazanavir, rimantandine, 
amantadine, zanamivir, oseltamivir, hydroxychloroquine, 
EIDD-2801 baricitinib, methylprednisolone, heparin, zinc, 
darunavir, emtricitabine, tenofovir, baloxavir marboxil, 
damageprevir, dipyridamole, fingolimod, losartan, azithro-
mycin, ribavirin, triazavirin, tranilast and ebastine (Wu, et al., 
2020; Araújo, et al., 2020; Dong, et al., 2020; Mckee et al., 
2020; Eastman, et al., 2020; Huang et al., 2020; Wang, 2020; 
Martinez, 2020).  
 
Among these drugs, the prodrug remdesivir stands out, which 
has been showing antiviral activity due to paramyxovirus, 
pneumovirus and some species of coronavirus infections, 
including SARS-CoV, Bat CoV and MERS-CoV (Eastman et 
al., 2020; Wu et al., 2020; Martinez, 2020).  Animal 
experiments were carried out, and it was found that the drug 
reduced the amount of virus in the lung tissue of mice infected 
with MERS-CoV, improving lung function (Dong, et al., 2020; 
Martinez, 2020). In tissue culture, remdesivir emitted effective 
semi-maximum fusions (EC 50. s) of 0.069 M for SARS-CoV 
and 0.074 M for MERS-CoV. And tissue culture studies have 
found that remdesivir is also active (EC 50) in submicromolar. 
And it differs against a number of coronaviruses, including 
CoVs OC43 (HCoV-OC43) and 229E (HCoV-229E). Thus, 
remdesivir has shown promise in inhibiting different CoV 
targets, presenting itself as an alternative for studies against 
SARS-CoV-2 (Martinez, 2020). 
 
Another drug that showed promise against SARS-CoV-2 was 
atazanavir in a study conducted by Araújo and collaborators 
(Araújo et al., 2020). That from DFT calculations, molecular 
docking and ADMET predictions, they could elucidate 
between 6 drugs, which has a higher molecular affinity to bind 
and inhibit the main SARS-CoV-2 (Mpro) protein. Thus, 
atazanavir had the lowest free binding energy when it binds to 
the Mpro or 3CLpro protein, responsible for mediating the 
replication and viral transcription of SARS-CoV-2, pointing to 
the strong action of the drug at the active site, causing damage 
to the protein and inhibiting the virus. We highlight the authors' 
recommendation for the use of this drug in studies with 
humans, having presented low toxicity and negative results for 
mutagenicity and carcinogenicity in a study by preADMET 
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Then we have the drug favipiravir, which is also presented as 
an alternative treatment for COVID-19, this drug was 
developed for the treatment of avian influenza and 
neuraminidase, in addition to being used to treat other 
infectious diseases caused by RNA viruses, such as influenza, 
Ebola and norovirus (Wang, 2020). Recent in vitro studies 
point to a redirection of favipiravir against SARS-CoV-2, 
which is a Beta-coronavirus consisting of single-stranded 
enveloped RNA (Barlow et al., 2020). We also present 
azithromycin, where in vitro studies have shown an inhibitory 
action against the Zika and Ebola viruses, which can prevent 
serious respiratory tract infections in patients suffering from 
viral infection (Gautret et al., 2020). Thus, based on these 
results, several studies have been carried out to elucidate 
possible effects of azithromycin associated with hydroxyl 
chloroquine in people infected with SARS-CoV-2 (Wang, 
2020). Hydroxychloroquine is derived from chloroquine 
hydroxy, which has a greater safety profile than chloroquine, 
both are drugs for the treatment of malaria (Gao et al., 2020). 
Evaluations point to the effectiveness of chloroquine to inhibit 
SARS-CoV-2 infection at low molar concentration. However, 
hydroxychloroquine has a greater cytotoxic potential, being 3 
times higher compared to chloroquine, and its use is more 
indicated in studies with humans infected with SARS-CoV-2 
(Barlow et al., 2020). A study with hydroxychloroquine 
showed inhibition of exacerbations of pneumonia, improving 
lung image and reducing disease progression in patients with 
COVID-19 (Gao et al., 2020). Ressaltamos que este método 
terapêutico até o momento não possui resultados contundentes 
sobre sua eficácia. We emphasize that this therapeutic method 
has so far had no striking results on its effectiveness. However, 
it has toxicological results that indicate health risks, which can 
cause adverse effects and worsen the patient's clinical 
condition, such as causing arrhythmias that can lead to death, 
in addition to presenting positive results for carcinogenicity in 
a study conducted by Araújo and collaborators (Fihn, et al., 
2020; Taylor and White, 2004; Juurlink, 2020; Araújo, et al., 
2020).  In addition to these possible treatment alternatives, 
other drugs have biological potential against SARS-CoV-2. 
Among them, we have arbidol, which is used in China and 
Russia for the prevention and treatment of influenza, in 
addition to other respiratory viral infections (Blaising et al., 
2014).  
 
Chinese scientists point to this drug as a possible treatment 
alternative against COVID-19. Other drugs that have antiviral 
activity are being analyzed, where darunavir, emtricitabine/ 
tenofovir and baloxavir present attractive preliminary results 
(Lythgoe and Middleton, 2020). Oseltamivir, on the other 
hand, did not obtain attractive results compared to SARS-CoV-
2 as pointed out in studies by Barlow and collaborators and 
Araújo and collaborators (Barlow et al., 2020)). We have also 
seen promising results with the use of EIDD-2801 which 
inhibited RNA-dependent-RNA-polymerase (RdRp) which 
catalyzes self-replication of single-stranded RNA and are key 
enzymes in viruses that have their single-stranded RNA 
genome, such as SARS-CoV-2. Like methylprednisolone, 
which inhibited anti-inflammatory cytokines, another 
compound that showed efficacy was heparin, which reverses 
the hypercoagulability of the potential mechanism of action of 
SARS-CoV-2. In addition to these, also have dipyridamole 
(inhibits phosphodiesterase), fingolimod (modulates 
sphingosine 1-phosphate receptor), losartan (blocks angiotensin 
receptor), ribavirin (inhibits protein synthesis and viral 
RNAm), triazarin (can inhibit RNA synthesis), tranilast 
(hematopoietic D synthesis prostaglandin inhibitor) and 
ebastine (inhibits H1) (Huang et al., 2020). Among all these 
drugs identified as a possible treatment alternative against 
SARS-CoV-2, remdesivir, atazanavir, favipiravir, EIDD-2801 
and hydroxychloroquine associated with azithromycin present 
themselves as the best therapeutic alternatives for studies in 
humans and to evaluate their effectiveness in treatment against 
COVID-19, where they presented preliminary results that 
reduced symptoms related to pneumonia in a percentage of 
infected patients (Holshue et al., 2020). In addition to being 
effective in molecular fitting to key SARS-CoV-2 proteins with 
free stable binding energies in computational studies by 
docking and molecular dynamics (Beck et al., 2020; Rodrigues 
et al., 2020). Another alternative is to strengthen the immune 
system through the use of Zn2+ associated with vitamin C as a 
prophylactic use in order to increase antiviral immunity, in 
addition to assisting the inflammatory response. Studies 
suggest that modulation of Zn2+ may be effective against 
SARS-CoV-2, through in vitro tests it could be observed that 
Zn2+ has antiviral activity inhibiting SARS-CoV RNA 
polymerase. However, clinical and experimental studies are 
needed to prove its effectiveness against the virus (Skalny et 
al., 2020). In this perspective, China conducts studies with 
natural products and synthetic compounds that may have 
biological potential against SARS-CoV-2 and have low 
toxicity and availability of active components. Preliminary 
results point to the interaction effectiveness and molecular fit 
of alcohol from patchouli, resveratrol, lignan and curcumin to a 
key SARS-CoV-2 protein (Huang et al., 2020).  
 
Patchouli alcohol is a compound of traditional Chinese 
medicine, patchouli, tricyclic sesquiterpene, which has 
biological and pharmacological information, including 
antivirals, anti-inflammatories, antioxidant immunomodulators. 
The anti-SARS-CoV-2 activity shown, shows that the binding 
and effect of patchouli alcohol on RdRp was promising, being 
able to promote antiviral activity (Huang et al., 2020).  
Curcumin is a phenolic compound isolated from turmeric that 
inhibits aminopeptidase N/CD13, the hypothesis being raised 
that it has efficacy as a prophylactic use against coronavirus, in 
order to inhibit its cell binding via the CD13 pathway and its 
entry into the host cell, in addition to hindering the replication 
of the virus in human cells as its action is observed in relation 
to other viral infections, such as HIV (Verma, 2020; Huynh et 
al., 2020). Two other potential phytotherapies under evaluation 
is lignan, which has an inhibitory activity against the 3CLpro or 
Mpro protein, responsible for the viral replication and 
transcription of SARS-CoV-2 and resveratrol, which prevents 
the expression of the virus’s RNA and nucleocapsid. The 
treatment with these western herbal medicines is mainly based 
on the principles of asymptomatic treatment, being a way to 
prevent complications (Huang et al., 2020). In addition to 
efforts to find an alternative treatment for SARS-CoV-2, 
studies aimed at developing vaccines are carried out with the 
aim of finding a definitive solution, however, this process is 
time-consuming and expensive (Amanat and Krammer, 2020; 
Ahmed  et al., 2020). Thus, tests of vaccine candidates are 
carried out following linear steps with several interruptions for 
data inspection and verification of the manufacturing method 
(Lurie, 2020). The discovery of a vaccine for SARS-CoV-2 
would control the spread of the virus and the therapeutic 
process (Ahmed et al., 2020). A previous study entitled 
“SARS-CoV-2 Vaccines: Status Report”, carried out by 
Amanat and Krammer (2020), shows the similarity between 
SARS-CoV and SARS-CoV-2, through phylogenetic analysis 
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of the complete genome of the two strains, where it was 
possible to elucidate the similarity in the cell entry mechanism 
and the use of human cell receptors (Wit  et al., 2020). Because 
of this similarity between the two viruses, previous research 
that has provided an understanding of the protective immune 
responses against SARS-CoV can potentially be used to help 
develop a vaccine for SARS-CoV-2. In this sense, more than 
140 candidates for vaccine against SARS-CoV-2 are being 
studied, with 9 recruited for clinical trials and available in the 
database of ClinicaTrial.gov (https://clinicaltrials.gov/) 




The SARS-CoV-2 pandemic caused scientists from all over the 
world to be engaged in the search for a treatment alternative, 
thus, a total of 4,898 studies were found related to the 
treatment alternative for SARS-CoV-2. However, a definitive 
solution has not yet been discovered, as the vaccine candidates 
are under analysis and need time for their results to be 
elucidated, with the studies of the University of Oxford being 
the most advanced. In contrast, drugs available in the 
pharmaceutical market for alternative use to fight SARS-CoV-
2, in particular the drugs remdesivir, atazanavir, favipiravir, 
EIDD-2801 and hydroxychloroquine associated with 
azithromycin presented attractive preliminary results and are 
recommended for clinical studies in as an alternative way of 
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